Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pain Linked to Inflammatory Lesions in Knee Osteoarthritis

Kathy Holliman  |  September 12, 2016

Inflammation in the knee was found to be associated with development of pain sensitization in recent research with a cohort from the Multicenter Osteoarthritis Study (MOST). This research finding may indicate that targeting of inflammation could help reduce pain severity in knee osteoarthritis (OA). Tuhina Neogi, MD, PhD, says that her and her colleagues’ research,…

Crossing the Line

When Medical Workforce Grievances Lead to Strikes

Simon M. Helfgott, MD  |  September 12, 2016

Picket Lines: June 27 was marked on my calendar as the day to watch. No doubt the union organizers shrewdly selected it to be their strike day because of its proximity to July 1, an auspicious date for teaching hospitals, when rookie interns and residents anxiously assume their heightened roles of responsibility within the medical…

Gout Treatment & Care Remain Suboptimal

Lara C. Pullen, PhD  |  September 12, 2016

A recent analysis compared the care of patients with RA with that received by patients with gout, finding that hospitalization and costs for patients with gout have increased, but both are decreasing for patients with RA. Unlike RA, significant advances in treatment have not been made for gout, despite its increasing prevalence, and patients may land in the hospital unnecessarily…

Advocacy Spotlight: Dr. Matt Heinz, Candidate for Congress from Arizona District 2 (Tucson)

From the College  |  September 9, 2016

RheumPAC is the ACR’s political action committee dedicated to increasing rheumatology’s presence on Capitol Hill. It is the only PAC dedicated to the interests of all rheumatologists and their patients. RheumPAC began in 2007 with the purpose of building contacts, influence and visibility within Washington, D.C. for rheumatology. RheumPAC works to support and elect pro-rheumatology…

The Real Story on RA: Survey Finds Communication Gaps Between Physicians & Patients with RA

Karen Appold  |  September 9, 2016

Survey results released earlier this year found that communication difficulties exist between patients and their rheumatologists for many reasons—possibly resulting in more disease activity despite advances in RA treatments. Here are tips for communicating with your patients and helping them be more proactive in their care…

Rheumatology Drug Updates: Ixekizumab Improves Work Productivity, plus Vobarilizumab Completes Phase 2 Trial in Rheumatoid Arthritis

Michele B. Kaufman, PharmD, BCGP  |  September 9, 2016

Ixekizumab Improves Work Productivity in Patients with Plaque Psoriasis Indirect costs of reduced work productivity can have a significant impact on a patient’s quality of life. A recent article published in JAMA Dermatology analyzed the results of three multicenter, randomized double-blind Phase 3 trials, UNCOVER-1, UNCOVER-2 and UNCOVER-3, which evaluated the effect of ixekizumab on…

Rheumatologist Richard M. Pope, MD, Was Honored at Northwestern University Symposium

Ann-Marie Lindstrom  |  September 8, 2016

When the head of the division steps down, how do you mark that event? The Feinberg School of Medicine, Northwestern University-Chicago hosted a day-long symposium to honor Richard M. Pope, MD, who had been chief of the division for 27 years, according to Harris Perlman, PhD, the new chief of the Division of Rheumatology. Richard…

Ethics Forum: Prescribing Teratogenic Medications to Adolescents Can Raise Confidentiality, Ethical Concerns

Karen B. Onel, MD, & Melissa Tesher, MD  |  September 8, 2016

Case A 17-year-old girl returns to the rheumatology clinic for scheduled follow-up for systemic lupus erythematosus (SLE). She is accompanied by her mother and father. She has a history of autoimmune cytopenias and Class III lupus nephritis. She has responded well to treatment with mycophenolate mofetil and hydroxychloroquine and was successfully weaned off of prednisone…

What Rheumatologists Should Know about Purchasing a Healthcare Practice

Steven M. Harris, Esq.  |  September 8, 2016

After extensive research and careful deliberation, you have finally made the exciting but daunting decision to purchase a healthcare practice. You know that in the next couple of months you are going to need to examine the practice from a different perspective—one of a future owner. You also recognize that in order to facilitate the…

Corticosteroid Use in Acute Polymyalgia Rheumatica Should be Reassessed

Arthur E. Brawer, MD  |  September 8, 2016

When I started my rheumatology practice 40 years ago, it quickly became apparent that many referrals of presumed polymyalgia rheumatica (PMR) patients and presumed giant cell arteritis (GCA) patients were the recipients of devastating side effects from long-term corticosteroid (CS) use that could not be discontinued due to prompt recurrence of inflammatory phenomena. It was…

  • « Previous Page
  • 1
  • …
  • 479
  • 480
  • 481
  • 482
  • 483
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences